U.S. Viscosupplementation Market Size & Outlook, 2023-2030
U.S. viscosupplementation market, 2018-2030 (US$M)
Related Markets
U.S. viscosupplementation market highlights
- The U.S. viscosupplementation market generated a revenue of USD 1,712.5 million in 2023 and is expected to reach USD 3,102.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.9% from 2024 to 2030.
- In terms of segment, three injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 1,712.5 million |
| Market revenue in 2030 | USD 3,102.2 million |
| Growth rate | 8.9% (CAGR from 2023 to 2030) |
| Largest segment | Three injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.5% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 3,102.2 million by 2030.
Three injection was the largest segment with a revenue share of 43.06% in 2023. Horizon Databook has segmented the U.S. viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
According to CDC, in 2013–2015, 54 million people in the U.S. were reported to be diagnosed with some form of arthritis. The condition has limited the activities of around 24 million adults and is responsible for severe joint pain in about 15 million adults.
The most common form of arthritis is osteoarthritis followed by rheumatoid arthritis, gout, and fibromyalgia. The rapid rise in geriatric population has led to increase in incidence of osteoarthritis, thus propelling demand for joint-injectable products.
According to Population Reference Bureau, the population of Americans aged 65 or older is projected to increase by twofold from 46 million in 2016 to 98 million by 2060. Multiple-injection products have existed in the market for a long time and, hence, are highly preferred.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. viscosupplementation market size, by product, 2018-2030 (US$M)
U.S. Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
